Dallas campus researchers present study findings to FDA


Hand-held Raman spectrometerTraditionally, compounded pharmaceuticals are quality checked through a “double-check” system where a second pharmacist does a paper check to ensure that compounded pharmaceuticals are prepared accurately. Unfortunately, the literature is replete with reports of compounding errors related to the use of the double-check method of quality control. With that in mind, a team of researchers from the Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy, Cook Children’s Health Care System in Fort Worth and Children’s Medical Center in Dallas have been working to improve this practice that is so common to compounding and reduce the number of compounding errors.

The researchers proposed a novel approach to assuring the quality of compounded pharmaceuticals through the use of hand-held Raman spectrometers. The results of their project, titled “Raman Spectroscopy: A Sensitive and Specific Technique for Determining the Accuracy of Compounded Pharmaceutical Formulations,” was recently published in the Journal of Pediatric Pharmacology and Therapeutics (21:413-8, 2016).

Because the study findings drew the attention of the U.S. Food and Drug Administration (FDA), School of Pharmacy researchers Claudia Meek, Ph.D., Trey Putnam, Ph.D., and Richard Leff, Pharm.D., were invited to speak about the study and its findings Dec. 15 at the FDA headquarters in Silver Springs, Maryland. More than 50 FDA officials — including several FDA directors — were invited to attend the presentation, which was part of FDA’s Critical Path Innovation Meetings.

Putnam said these preliminary studies demonstrated that the novel technique provided “robust quantitative information on the identity and the concentration of the formulation’s components.” In conclusion, he added, the investigators found that utilizing hand-held Raman spectrometers as a quality control measure is accurate, quantitative, rapid and cost-effective.

“The dialogue during the meeting was robust,” Putnam said. “FDA is interested in watching the future directions of our research.”

Related Stories

Summer Program Introduces Medical Students to the Research Laboratory

Each year, approximately 100 first-year TTUHSC School of Medicine students — more than half of the Lubbock class — step out of the classroom and into the laboratory to spend part of their summer making unique discoveries through the Medical Student Summer Research Program (MSSRP).

Texas Tech University Health Sciences Center School of Nursing Named Best Accelerated Bachelor of Science in Nursing Program in Texas

The TTUHSC School of Nursing Accelerated Bachelor of Science in Nursing (BSN) program has been ranked the No. 1 accelerated nursing program in Texas by RegisteredNursing.org.

TTUHSC Names New Regional Dean for the School of Nursing

Louise Rice, DNP, RN, has been named regional dean of the TTUHSC School of Nursing on the Amarillo campus.

Recent Stories

Summer Program Introduces Medical Students to the Research Laboratory

Each year, approximately 100 first-year TTUHSC School of Medicine students — more than half of the Lubbock class — step out of the classroom and into the laboratory to spend part of their summer making unique discoveries through the Medical Student Summer Research Program (MSSRP).

Research

TTUHSC Researcher Awarded CPRIT Grant to Study Type of Pediatric Bone Cancer

CPRIT recently awarded a two-year, $198,822 grant to Balakrishna Koneru, Ph.D., an assistant professor of pediatrics at TTUHSC’s School of Medicine and Graduate School of Biomedical Sciences.

Education

From Classroom to Clinic: Building the Future of Speech-Language Pathology

The Clinical Experience Course in the Speech, Language and Hearing Sciences program at TTUHSC provides students with hands-on, practical application of the theoretical knowledge learned in the classroom.